Truist Securities Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Srikripa Devarakonda has reiterated a Buy rating on Keros Therapeutics (NASDAQ:KROS) and maintained a $100 price target.
March 13, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities reaffirms a Buy rating on Keros Therapeutics with a $100 price target.
The reiteration of a Buy rating and maintenance of a $100 price target by a reputable analyst like Srikripa Devarakonda from Truist Securities could instill confidence among investors and potentially lead to a positive short-term price movement for Keros Therapeutics.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100